Blood pressure goals and arterial stiffness in chronic kidney disease

Journal of Clinical Hypertension

Volumn 11, Issue 4, 2009, Pages 201-206

  Liew, YinPing ^a   Rafey, Mohammed A ^a   Allam, Sridhar ^b   Arrigain, Susana ^a   Butler, Robert ^a   Schreiber, Martin ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

ADULT; AGE; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CAUCASIAN; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GOAL ATTAINMENT; HEIGHT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; SEX;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRACHIAL ARTERY; CHRONIC DISEASE; COMORBIDITY; CROSS-SECTIONAL STUDIES; ELASTICITY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 65449119940     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00096.x     Document Type: Article

References (35)

1. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307-1315.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(suppl 3):S112-S119.
3. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the american heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003; 108: 2154-2169.
4. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the united states renal data system 2004 annual data report: Atlas of end-stage renal disease in the united states. Am J Kidney Dis. 2005;45:S1-S280.
5. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
6. DeLoach SS, Townsend RR. Vascular stiffness: Its measurement and significance for epidemiologic and outcome studies. Clin J Am Soc Nephrol. 2008;3:184-192.
7. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. HOT study group. Lancet. 1998;351:1755-1762.
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK prospective diabetes study group. BMJ. 1998;317:703-713.
9. Chobanian AV, Bakris GL, Black HR, et.al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003;289:2560-2572.
10. Hashimoto J, Imai Y, O'Rourke MF. Indices of pulse wave analysis are better predictors of left ventricular mass reduction than cuff pressure. Am J Hypertens. 2007;20:378-384.
11. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: The strong heart study. Hypertension. 2007;50:197-203.
12. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the conduit artery function evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
13. Safar ME, Blacher J, Pannier B, et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension. 2002;39:735-738.
14. Wang MC, Tsai WC, Chen JY, et al. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis. 2005;45:494-501.
15. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236-1241.
16. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension. 2002;39:10-15.
17. Blacher J, Asmar R, Djane S, et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension. 1999;33:1111-1117.
18. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103:987-992.
19. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation. 2003;107:2864-2869.
20. Boutouyrie P. New techniques for assessing arterial stiffness. Diabetes Metab. 2008;34(suppl 1):S21-S26.
21. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens. 2005;18(1 Pt 2):3S-10S.
22. Nurnberger J, Keflioglu-Scheiber A, Opazo Saez AM, et al. Augmentation index is associated with cardiovascular risk. J Hypertens. 2002;20:2407-2414.
23. Weber T, Auer J, O'Rourke MF, et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation. 2004;109:184-189.
24. Mitchell GF, Parise H, Benjamin EJ, et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: The framingham heart study. Hypertension. 2004;43:1239-1245.
25. Walker WG, Neaton JD, Cutler JA, et al. Renal function change in hypertensive members of the multiple risk factor intervention trial. Racial and treatment effects. The MRFIT research group. JAMA. 1992;268:3085-3091.
26. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National kidney foundation hypertension and diabetes executive committees working group. Am J Kidney Dis. 2000;36:646-661.
27. O'Rourke MF, Hashimoto J. Arterial stiffness: A modifiable cardiovascular risk factor? J Cardiopulm Rehabil Prev. 2008;28:225-237.
28. Asmar RG, London GM, O'Rourke ME, et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/ indapamide combination in hypertensive patient: A comparison with atenolol. Hypertension. 2001;38:922-926.
29. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
30. de Luca N, Asmar RG, London GM, et al. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/ indapamide in hypertensive subjects. J Hypertens. 2004;22:1623-1630.
31. Franklin SS. Arterial stiffness and hypertension: A two-way street? Hypertension. 2005;45:349-351.
32. Benetos A, Adamopoulos C, Bureau JM, et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation. 2002;105:1202-1207.
33. Liao D, Arnett DK, Tyroler HA, et al. Arterial stiffness and the development of hypertension. The ARIC study. Hypertension. 1999;34:201-206.
34. Howard BV, Roman MJ, Devereux RB, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: The SANDS randomized trial. JAMA. 2008;299:1678-1689.
35. Sarafidis PA, Li S, Chen SC, et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008;121:332-340.